Pure Global

Evaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland China - Trial NCT06332014

Access comprehensive clinical trial information for NCT06332014 through Pure Global AI's free database. This Phase 4 trial is sponsored by Amgen and is currently Not yet recruiting. The study focuses on Osteoporosis. Target enrollment is 100 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06332014
Phase 4
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06332014
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Evaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland China
A Phase 4 Single Arm Open Label Study for the Efficacy and Safety of Prolia in Treatment of Male Subjects With Osteoporosis in Mainland China

Study Focus

Osteoporosis

Prolia

Interventional

drug

Sponsor & Location

Amgen

Timeline & Enrollment

Phase 4

Jul 31, 2024

Jul 29, 2026

100 participants

Primary Outcome

Percent change from baseline in bone mineral density (BMD) of lumbar spine at month 12

Summary

The primary objective of this study is to evaluate the efficacy of Prolia on lumbar spine BMD
 at 12 months.

ICD-10 Classifications

Osteoporosis, unspecified
Other osteoporosis
Idiopathic osteoporosis
Osteoporosis in diseases classified elsewhere
Postmenopausal osteoporosis

Data Source

ClinicalTrials.gov

NCT06332014

Non-Device Trial